Cerebral pattern of pro- and anti-inflammatory cytokines in dementias

Brain Research Bulletin

Volumn 61, Issue 3, 2003, Pages 255-260

  Tarkowski, Elisabeth ^a   Liljeroth, Ann Marie ^b   Minthon, Lennart ^b   Tarkowski, Andrzej ^a   Wallin, Anders ^a   Blennow, Kaj ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Apoptosis; Cytokines; Dementia; Gene polymorphism

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; LYMPHOTOXIN; PROTEIN BCL 2; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ALZHEIMER DISEASE; APOPTOSIS; CEREBROSPINAL FLUID LEVEL; CONFERENCE PAPER; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DNA POLYMORPHISM; HUMAN; MULTIINFARCT DEMENTIA; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; WHITE MATTER;

EID: 0043092058     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-9230(03)00088-1     Document Type: Conference Paper

References (51)

1. Allsopp T.E., Wyatt A., Paterson H.F., Davies A.M. The protooncogen bcl-2 can selectively rescue neurotrophic-factor dependent neurons from apoptosis. Cell. 73:1993;295-307.
2. Anderson A.J., Cummings B.J., Cotman C.W. Increased immunoreactivity of jun- and fos-related proteins in Alzheimer's disease: association with pathology. Exp. Neurol. 125:1994;286-295.
3. Anderson A.J., Su J.H., Cotman C.W. DNA damage and apoptosis in Alzheimer's disease: colocalization with c-jun immunoreactivity, relationship to brain area, and effect of postmortem delay. J. Neurosci. 16:1996;1710-1719.
4. R.B. Banati, K. Beyreuter, Alzheimer's disease, in: H. Kettenman, B.R. Ransom (Eds.), Neuroglia, Oxford University Press, New York, Oxford, 1995, pp. 1027-1043.
5. 2+ accumulation. Proc. Natl. Acad. Sci. U.S.A. 92:1995;9328-9332.
6. Bauer J., Ganter U., Strauss S., Stadtmuller G., Frommberger U., Bauer H., Volk B., Berger M. The participation of interleukin-6 in the pathogenesis of Alzheimer's disease. Forty-fifth forum in Immunology. Res. Immunol. 143:1992;650-657.
7. Beamer N.B., Coull B.M., Clark W.M., Hazel J.S., Silberger J.R. Interleukin-6 and interleukin-1 receptor antagonist in acute stroke. Ann. Neurol. 37:1995;800-804.
8. Blennow K., Wallin A., Gottfries C.G. Presence of parieto-temporal symptomatology distinguishes early- and late-onset Alzheimer disease. Int. J. Geriatr. 6:1991;149-156.
9. Brenneman D.E., Schultzberg M., Bartfai T., Gozes I. Cytokine regulation of neuronal survival. J. Neurochem. 58:1992;454-460.
10. Cheng B., Christakos S., Mattson M.P. Tumor necrosis factors protect neurons against metabolic-excitotoxic insults and promote maintenance of calcium homeostasis. Neuron. 12:1994;139-153.
11. Dinarello C.A., Thompson R.C. Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol. Today. 12:1991;404-410.
12. Frei K., Malipiero U.V., Leist T.P., Zinckernagel R.M., Schwab M.E., Fontana A. On the cellular source and function of interleukin-6 produced in the central nervous system in viral diseases. Eur. J. Immunol. 19:1989;689-694.
13. Garlind A., Brauner A., Höjeberg B., Basun H., Schultzberg M. Soluble interleukin-1 receptor type II levels are elevated in the cerebrospinal fluid in Alzheimer's disease patients. Brain Res. 826:1999;112-116.
14. Goldgaber D., Harris H.W., Hla T., Maciag T., Donnely R.J., Jacobsen J.S., Vitek M.P., Gajdusek D.C. Interleukin 1 regulates synthesis of amyloid β-protein precursor mRNA in human endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 86:1989;7606-7610.
15. Griffin W.S.T., Stanley L.C., Ling C., White L., MacLeod V., Perrot L.J., White C.L., Araoz C. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 86:1989;7611-7615.
16. Hama T., Miyamoto M., Tsukui H., Nishio C., Hatanaka H. Interleukin-6 as a neurotrophic factor for promoting the survival of cultured basal forebrain cholinergic neurons from postnatal rats. Neurosci. Lett. 104:1989;340-344.
17. K. Iqbal, Prevalence and neurobiology of Alzheimer disease: some highlights, in: K. Iqbal, D.R.C. McLachlan, B. Winblad, H.M. Wisniewski (Eds.), Alzheimer's Disease: Basic Mechanisms, Diagnosis and Therapeutic Strategies, Wiley-Interscience Publication, Chichester, 1991, pp. 9-12.
18. Itoh N., Nagata S. A novel protein domain required for apoptosis. J. Biol. Chem. 268:1993;10932-10937.
19. Kroeger K.M., Carville K.S., Abraham L.J. The -308 tumor necrosis factor α promotor polymorphism effects transcription. Mol. Immunol. 34:1997;391-399.
20. Lanzrein A.-S., Johnston C.M., Perry V.H., Jobst K.A., King E.M., Smith A.D. Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1β, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-α, the soluble tumor necrosis factor receptors I and II, and α1-antichymotrypsin. Alzheimer Dis. Assoc. Disord. 3:1998;215-227.
21. Li Y.-P., Bushnell A.F., Lee C.-M., Perlmutter L.S., Wong S.K.-F. β-Amyloid induces apoptosis in human-derived neurotypic SH-SY 5Y cells. Brain Res. 738:1996;196-204.
22. Lieberman A.P., Pitha P.M., Shin H.S., Shin M.L. Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotrop virus. Proc. Natl. Acad. Sci. U.S.A. 86:1989;6348-6352.
23. Loo D.T., Copani A., Pike C.J., Whittemore E.R., Walencewicz A.J., Cotman C.W. Apoptosis is induced by β-amyloid in cultured central nervous neurons. Proc. Natl. Acad. Sci. U.S.A. 90:1993;7755-7951.
24. Martinou J., Dubois-Dauphin M., Staple J., Frankowski H., Missotten M., Albertini P., Talabot D., Catsicas S., Pietra C. Overexpression of bcl-2 in transgenic mice protects neurons from naturally occurring death and experimental ischemia. Neuron. 13:1994;1017-1030.
25. Matsuyama T., Hata R., Yamamoto Y., Tagaya M., Akita H., Uno H., Wanaka A., Furuyama J., Sugita M. Localization of Fas antigen m-RNA induced in postischemic murine forebrain by the in situ hybridization. Mol. Brain Res. 34:1995;166-172.
26. McGeer P.L., Akiyama H., Itagaki S., McGeer E.G. Immune system response in Alzheimer's disease. Can. J. Neurol. Sci. 16:1989;516-527.
27. McGeer P.L., Itagaki S., Tago H., McGeer E.G. Reactive microglia in patients with senile dementia of Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci. Lett. 79:1987;195-200.
28. McLaurin J., D'Souza S., Stewart J., Blain M., Beaudet A., Nalbantoglu J., Antel J.P. Effect of tumor necrosis factor α and β on humans oligodendrocytes and neurons in culture. Int. J. Dev. Neurosci. 13:1995;369-381.
29. McManus R., Wilson A.G., Mansfield J., Weir D.G., Duff G.W., Kelleher D. TNF2, a polymorphism of the tumor necrosis-α gene promoter, is a component of the celiac disease major histocompatibility complex haplotype. Eur. J. Immunol. 26:1996;2113-2118.
30. Meda L., Cassatella M.A., Szendrei G.I., Otvos L., Baron P., Villalba M., Ferrari D., Rossi F. Activation of microglial cells by β-amyloid protein and interferon-γ Nature. 374:1995;647-650.
31. Messer G., Spengler U., Jung M.C., Honold C., Blömer K., Pape G.R., Riethmuller G., Weiss E.H. Polymorphic structure of the tumor necrosis factor (TNF) locus: an Ncol polymorphism in the first intron of the human TNF-α gene correlates with a variant amino acid in position 26 and a reduced level of TNF-α production. J. Exp. Med. 173:1991;209-219.
32. Paradis E., Douillard H., Koutroumanis M., Goodyer C., LeBlanc A. Amyloid β peptide of Alzheimer's disease downregulates bcl-2 and upregulates Bax expression in human neurons. J. Neurosci. 16:1996;7533-7539.
33. Pociot F., Brian T.L., Jongeneel C.V., Mölvig J., Worsaae H., Abbal M., Thomsen M., Nerup J., Cambon-Thomsen A. Association of tumor necrosis factor (TNF) and class II major histocompatibility complex alleles with the secretion of TNF-α and TNF-β by mononuclear cells: a possible link to insulin-dependent diabetes mellitus. Eur. J. Immunol. 23:1993;224-231.
34. Relton J.K., Rothwell N.J. Interleukin-1 receptor antagonist inhibits ischemic and excitotoxic neuronal damage in the rat. Brain Res. Bull. 29:1992;243-246.
35. Righi M., Mori L., De Libero G., Sironi M., Biondi A., Mantovani A.D., Domini S., Ricciardi-Castagnoli P. Monokine production by microglial cell clones. Eur. J. Immunol. 19:1989;1443-1448.
36. M. Rossor, Disorders of psychic function. Dementia, in: A.K. Asbury, G.M. McKhann, W.I. McDonald (Eds.), Disease of the Nervous System: Clinical Neurobiology, 2nd ed., W.B Saunders Company, Philadelphia, 1992, pp. 788-794.
37. Satoh T., Nakamura S., Taga T., Matsuda T., Hirano T., Kishimoto T., Kasiro Y. Induction of neuronal differentiation in PC12 cells by B-cell stimulatory factor 2/interleukin 6. Mol. Cell. Biol. 8:1988;3546-3549.
38. Schwartz M., Solomon A., Lavie V., Ben B.S., Belkin M., Cohen A. Tumor necrosis factor facilitates regeneration of injured central nervous system axons. Brain Res. 545:1991;334-338.
39. B.A. St Pierre, J.E. Merill, J.M. Dopp, Effects of cytokines on the CNS cells: glia, in: R.M. Ransohoff, E.N. Benveniste (Eds.), Cytokines and the CNS, CRC press, Boca Raton, Florida, 1996, pp. 151-168.
40. Stuber F., Petersen M., Bokelmann F., Schade U. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-α concentrations and outcome of patients with severe sepsis. Crit. Care Med. 24:1996;381-384.
41. Sutton E.T., Thomas T., Bryant M.W., Landon C.S., Newton C.A., Rhodin J.A. Amyloid-beta peptide induced inflammatory reaction is mediated by the cytokines tumor necrosis factor and interleukin-1. J. Submicrosc. Cytol. Pathol. 31:1999;313-323.
42. Tarkowski E., Liljeroth A.-M., Minthon L., Blennow K. Nilsson, Decreased levels of intrathecal IL-1 receptor antagonist in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 12:2001;314-317.
43. Tarkowski E., Liljeroth A.-M., Nilsson Å., Ricksten A., Davidsson P., Minthon L., Blennow K. TNF gene polymorphism and its relation to intracerebral production of TNF-α and -β in AD. Neurology. 54:2000;2077-2081.
44. Tarkowski E., Rosengren L., Blomstrand C., Wikkelsö C., Jensen C., Ekholm S., Tarkowski A. Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke. Stroke. 26:1995;1393-1398.
45. Tarkowski E., Wallin A., Blennow K., Tarkowski A. Local production of TNF-α, a potent neuroprotective agent, in Alzheimer disease and vascular dementia. J. Clin. Immunol. 19:1999;223-230.
46. Tarkowski E., Rosengren L., Blomstrand C., Wikkelsö C., Jensen C., Ekholm S., Tarkowski A. Intrathecal release of pro- and antiinflammatory cytokines in stroke. Clin. Exp. Immunol. 110:1997;492-499.
47. Tracey, Tumor necrosis factor-alpha, in: A.W. Thomson (Ed.), The Cytokine Handbook, 2nd ed., vol. 19, Academic Press, London, 1994, pp. 343-369.
48. Vandenabeele P., Fiers W. Is amyloidogenesis during Alzheimer's disease due to an IL-1-/IL-6-mediated "acute phase response" in the brain? Immunol. Today. 12:1991;217-219.
49. Wilson A.G., de Vries N., Pociot F., di Giovine F.S., van der Putte L.B.A., Duff G.W. An allelic polymorphism within the human tumor necrosis factor α promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J. Exp. Med. 177:1993;557-560.
50. Wilson A.G., di Giovine F.S., Duff G.W. Genetics of tumor necrosis factor-α in autoimmune, infectious, and neoplastic diseases. J. Inflamm. 45:1995;1-12.
51. Wilson A.G., Symons J.A., McDowell T.L., McDevitt H.O., Duff G.W. Effects of a polymorphism in the human tumor necrosis factor α promoter on transcriptional activation. Proc. Natl. Acad. Sci. U.S.A. 94:1997;3195-3199.